- Home
- LODE vs KPTI Comparison
LODE vs KPTI Comparison
Compare LODE & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LODE
- KPTI
- Stock Information
- Founded
- LODE 2008
- KPTI 2008
- Country
- LODE United States
- KPTI United States
- Employees
- LODE N/A
- KPTI N/A
- Industry
- LODE Major Chemicals
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- LODE Industrials
- KPTI Health Care
- Exchange
- LODE Nasdaq
- KPTI Nasdaq
- Market Cap
- LODE 53.0M
- KPTI 44.5M
- IPO Year
- LODE N/A
- KPTI 2013
- Fundamental
- Price
- LODE $3.86
- KPTI $4.42
- Analyst Decision
- LODE Buy
- KPTI Buy
- Analyst Count
- LODE 1
- KPTI 6
- Target Price
- LODE $26.00
- KPTI $48.50
- AVG Volume (30 Days)
- LODE 629.7K
- KPTI 72.1K
- Earning Date
- LODE 08-07-2025
- KPTI 08-05-2025
- Dividend Yield
- LODE N/A
- KPTI N/A
- EPS Growth
- LODE N/A
- KPTI N/A
- EPS
- LODE N/A
- KPTI N/A
- Revenue
- LODE $3,376,027.00
- KPTI $142,126,000.00
- Revenue This Year
- LODE $33.58
- KPTI $2.09
- Revenue Next Year
- LODE N/A
- KPTI $12.90
- P/E Ratio
- LODE N/A
- KPTI N/A
- Revenue Growth
- LODE 102.20
- KPTI 1.19
- 52 Week Low
- LODE $1.26
- KPTI $3.51
- 52 Week High
- LODE $10.10
- KPTI $17.40
- Technical
- Relative Strength Index (RSI)
- LODE 72.48
- KPTI 44.98
- Support Level
- LODE $3.47
- KPTI $4.22
- Resistance Level
- LODE $4.25
- KPTI $4.62
- Average True Range (ATR)
- LODE 0.23
- KPTI 0.30
- MACD
- LODE 0.05
- KPTI 0.06
- Stochastic Oscillator
- LODE 82.56
- KPTI 56.41
About LODE Comstock Inc.
Comstock Inc innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock's innovations group is engaged in developing and using artificial intelligence technologies for advanced materials development.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.